The National Institutes of Health (NIH) has granted $2.1 million to UCLA’s Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) and the UCLA-CDU Center for AIDS Research (CFAR) to support four research projects and an implementation science consultation hub.
Mosaic Therapeutics appoints Dr Barry Davies as CSO
Dr. Barry Davies joins Mosaic Therapeutics as CSO, bringing 25 years of drug discovery expertise to advance targeted oncology therapies and precision medicine.